Clínic Hospital

Cuts in international HIV funding could cause between 4.4 million and 10.8 million new HIV infections between 2025 and 2030 in 26 low- and middle-income countries. In addition, these funding reductions could result in between 770,000 and 2.9 million HIV-related deaths, according to a study published in The Lancet HIV. Five countries that together provide more than 90% of funding for international HIV interventions - the US, UK, France, Germany and the Netherlands - have announced reductions in funding between now and 2026, the article explains. This includes the immediate suspension, in January 2025, of US funding, which accounted for nearly three-quarters of the total.

In marathon runners, the myelin content of specific regions of the brain is reversibly reduced, according to a study carried out in the Basque Country. This observation is consistent with animal evidence suggesting that myelin lipids - a substance that surrounds neurons - can act as energy reserves in extreme metabolic conditions, as detailed by the authors in Nature Metabolism. The analysis is based on magnetic resonance imaging of eight men and two women before and after running a marathon. According to the study, the myelin content was fully recovered two months after the race.

According to the World Health Organisation (WHO), the prevalence of obesity worldwide has increased by more than 100 % between 1990 and 2022. This reality has been and is constantly reflected in the media, but not always narrated or illustrated in the right way. Here are some tips on how to report on this disease from experts, international guidelines and specialised image banks.

According to a new study published in Science, a machine learning-based artificial intelligence (AI) system - called Mal-ID - can decipher an individual's history of infections and diseases in the immune system. The authors say this provides a powerful tool with the potential to accurately diagnose autoimmune disorders, viral infections and vaccine responses.

A team of US researchers has followed some patients treated with CAR-T therapies in a small clinical trial conducted between 2004 and 2009 to treat children with neuroblastoma, a nerve cell tumor that can have a poor prognosis. At least one of them, a woman who was treated with CAR-T as a child, remains in remission 18 years later, the longest duration of such therapy described to date. The results are published in the journal Nature Medicine. 

Exposure to cold and heat could affect adolescents' mental health, according to a study published in JAMA Network Open. The research, led by the Barcelona Institute for Global Health (ISGlobal), was conducted with nearly 5,000 adolescents from the Netherlands (3,934) and Spain (885). The results showed how exposure to environmental temperatures influences psychiatric symptoms such as anxiety, depression, and attention problems.

Science magazine has named lenacapavir as breakthrough of the year. Lenacapavir is an injectable drug that prevents HIV infection for six months with near 100% efficacy. The publication notes its potential to dramatically reduce infections in high-risk populations, but also reminds that global roll-out will depend on affordability, manufacturing agreements and a robust health infrastructure. Approval of the drug is expected by 2025. 

CAR-T cell-based treatments have been successful against some blood tumours, but are much less effective for solid tumours. A phase 1 clinical trial has tested their use in 11 children and young adults with diffuse midline glioma, a tumour of the nervous system that is considered incurable. The results, published in the journal Nature, indicate that the treatment improved functional status in nine of the 11 patients. One of the four who showed a strong response is still healthy four years later.

The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.

The regulatory agencies for medicines in the United States and Europe have issued statements informing about a possible risk of developing certain types of tumors following CAR-T cell immunotherapy treatment. What do we know so far? What is the real risk? Does the benefit-risk balance still hold? Has anything changed after these alerts? We answer these questions with expert opinions and the data currently available.